Approaches for dosage individualisation in critically ill patients

Bibliography

• Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin 2006;22:255-71
   PubMed Web of Science ®Google Scholar
• Eyler RF, Mueller BA. Antibiotic dosing in critically ill patients with acute kidney injury. Nat Rev Nephrol 2011;7:226-35
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005;44(10):1009-34
   PubMed Web of Science ®Google Scholar
• McKenzie C. Antibiotic dosing in critical illness. J Antimicrob Chemother 2011;66(Suppl 2):ii25-31
   PubMed Web of Science ®Google Scholar
• Roberts JA, Ulldemolins M, Michael S, et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Ag 2010;36:332-9
   PubMed Web of Science ®Google Scholar
• Sime FB, Roberts MS, Peake SL, et al. Does beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review. Ann Intensive Care 2012;2(1):35
   PubMed Web of Science ®Google Scholar
• Hayashi Y, Lipman J, Andrew A, et al. Beta-lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia. Int J Antimicrob Ag 2013;41:162-6
   PubMed Web of Science ®Google Scholar
• Kruger PS, Freir NM, Venkatesh B, et al. A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. Intensive Care Med 2009;35:717-21
   PubMed Web of Science ®Google Scholar
• von Winckelmann SL, Spriet I, Willems L. Therapeutic drug monitoring of phenytoin in critically ill patients. Pharmacotherapy 2008;28(11):1391-400
   PubMed Web of Science ®Google Scholar
• Escobar L, Gai MN, Regueira T, Andresen M. Consideraciones farmacocinéticas en el paciente crítico. Rev Med Chile 2012;140:780-8
   PubMedGoogle Scholar
• Varghese JM, Roberts JA, Lipman J. Pharmacokinetics and pharmacodynamics in critically ill patients. Curr Opin Anaesthesiol 2010;23:472-8
   PubMed Web of Science ®Google Scholar
• Mehrotra R, De Gaudio R, Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 2004;30:2145-56
   PubMed Web of Science ®Google Scholar
• Roberts J, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009;37(3):840-51
   PubMed Web of Science ®Google Scholar
• Liu X, Kruger PS, Roberts MS. How to measure pharmacokinetics in critically ill patients? Curr Pharm Biotechnol 2011;12(12):2037-43
   PubMed Web of Science ®Google Scholar
• Au Yeung SC, Ensom MH. Phenytoin and enteral feedings: does evidence support an interaction? Ann Pharmacother 2000;34(7-8):896-905
   PubMed Web of Science ®Google Scholar
• Gonzalez D, Conrado DJ, Theuretzbacher U, Derendorf H. The effect of critical illness on drug distribution. Curr Pharm Biotechnol 2011;12:2030-6
   PubMed Web of Science ®Google Scholar
• Roberts JA. Using PK/PD to optimize antibiotic dosing for critically ill patients. Curr Pharm Biotechnol 2011;12:2070-9
   PubMed Web of Science ®Google Scholar
• Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams. Crit Care 2011;15(5):R206
   PubMed Web of Science ®Google Scholar
• Roberts JA, Pea P, Lipman L. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet 2013;52:1-8
   PubMed Web of Science ®Google Scholar
• Ulldemolins M, Roberts JA, Rello J, et al. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011;50(2):99-110
   PubMed Web of Science ®Google Scholar
• Finfer S, Bellomo R, McEvoy S, et al. Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation: the SAFE study. BMJ 2006;333(7577):1044
   PubMed Web of Science ®Google Scholar
• Hinderling PH, Hartmann D. The pH dependency of the binding of drugs to plasma proteins in man. Ther Drug Monit 2005;27(1):71-85
   PubMed Web of Science ®Google Scholar
• Álvarez-Lerma F, Olaechea P, Grau S, et al. Grupo de Estudio de Infección en el paciente crítico (GEIPC-SEIMC). Recommendations for antibiotic monitoring in ICU patients. Enferm Infecc Microbiol Clin 2008;26(4):230-9
   PubMed Web of Science ®Google Scholar
• Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984;77(4):657-62
   PubMed Web of Science ®Google Scholar
• Van Zanten ARH, van der Meer YG. Prolonged infusion of carbapenems in critically ill patients: time to extend our practice. Crit Care Med 2013;41(2):676-7
   PubMed Web of Science ®Google Scholar
• Jones DP, Aw TY, Shan XQ. Drug metabolism and toxicity during hypoxia. Drug Metab Rev 1989;20:247-60
   PubMed Web of Science ®Google Scholar
• Park GR. Molecular mechanisms of drug metabolism in the critically ill. Br J Anaesth 1996;77:32-49
   PubMed Web of Science ®Google Scholar
• Le Couteur DG, Fraser R, Hilmer S, et al. The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet 2005;44:187-200
   PubMed Web of Science ®Google Scholar
• Renton KW. Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab 2004;5:235-43
   PubMed Web of Science ®Google Scholar
• Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008;64:1147-61
   PubMed Web of Science ®Google Scholar
• Frye RF, Zgheib NK, Matzke GR, et al. Liver disease selectively modulates cytochrome P-450 metabolism. Clin Pharmacol Ther 2006;80:235-45
   PubMed Web of Science ®Google Scholar
• Potter JM, Hickman PE, Lynch SV, et al. Use of monoethylglycinexylidide as a liver function test in the liver transplant recipient. Transplantation 1993;56(6):1385-8
   PubMed Web of Science ®Google Scholar
• Udy AA, Roberts JA, Robert J, et al. Augmented renal clearance. Implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010;49(1):1-16
   PubMed Web of Science ®Google Scholar
• Bouman CS. Antimicrobial dosing strategies in critically ill patients with acute kidney injury and high-dose continuous veno-venous hemofiltration. Curr Opin Crit Care 2008;14:654-9
   PubMed Web of Science ®Google Scholar
• Spooner AM, Deegan C, D'Arcy DM, et al. An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration. BMC Clin Pharmacol 2011;11:11
   PubMedGoogle Scholar
• Li AM, Gomersall CD, Choi G, et al. A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data? J Antimicrob Chemother 2009;64(5):929-37
   PubMed Web of Science ®Google Scholar
• Lautrette A, Phan TN, Ouchchane L, et al. High creatinine clearance in critically ill patients with community-acquired acute infectious meningitis. BMC Nephrol 2012;13:124
   PubMedGoogle Scholar
• Herrera-Gutierrez ME, Seller-Perez G, Banderas-Bravo E, et al. Replacement of 24-h creatinine clearance by 2-h creatinine clearance in intensive care unit patients: a single-center study. Intensive Care Med 2007;33(11):1900-6
   PubMed Web of Science ®Google Scholar
• Papadopoulos J, Smithburger PL. Common drug interactions leading to adverse drug events in the intensive care unit: management and pharmacokinetic considerations. Crit Care Med 2010;38:S126-35
   PubMed Web of Science ®Google Scholar
• Joffe A, Wood K. Obesity in critical care. Curr Opin Anaesthesiol 2007;20(2):113
   PubMed Web of Science ®Google Scholar
• Falagas ME, Karageorgopoulos DE. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 2010;375:248-51
   PubMed Web of Science ®Google Scholar
• Sánchez Navarro A, Colino Gandarillas CI, Alvarez Lerma F, et al. Pharmacokinetics and pharmacodynamics of levofloxacin in intensive care patients. Clin Pharmacokin 2005;44(6):627-35
   PubMed Web of Science ®Google Scholar
• Bienert A, Wiczling P, Grzeoekowiak E, et al. Potential pitfalls of propofol target controlled infusion delivery related to its pharmacokinetics and pharmacodynamics. Pharmacol Rep 2012;64(4):782-95
   PubMed Web of Science ®Google Scholar
• Howard ML, Hill JJ, Galluppi GR, McLean MA. Plasma protein binding in drug discovery and development. Comb Chem High Throughput Screen 2010;13(2):170-87
   PubMed Web of Science ®Google Scholar
• Briscoe SE, McWhinney BC, Lipman J, et al. A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2012;907:178-84
   PubMed Web of Science ®Google Scholar
• Musteata FM. Calculation of normalized drug concentrations in the presence of altered plasma protein binding. Clin Pharmacokinet 2012;51(1):55-68
   PubMed Web of Science ®Google Scholar
• Garot D, Respaud R, Lanotte P, et al. Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal. Br J Clin Pharmacol 2011;72(5):758-67
   PubMed Web of Science ®Google Scholar
• Liu P, Müller M, Derendorf H. Rational dosing of antibiotics: the use of plasma concentration versus tissue concentration. Int J Antimicrob Ag 2002;19(4):285-90
   PubMed Web of Science ®Google Scholar
• Joukhadar C, Müller M. Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future. Clin Pharmacokinet 2005;4(9):895-913
   Google Scholar
• Bartal C, Danon A, Schlaeffer F, et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med 2003;114(3):194-8
   PubMed Web of Science ®Google Scholar
• Buijk SE, Mouton JW, Gyssens IC, et al. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 2002;28(7):936-42
   PubMed Web of Science ®Google Scholar
• Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness of therapeutic drug monitoring. A systematic review. Ther Drug Monit 2005;27(1):12-17
   Google Scholar
• Beumer JH. Without therapeutic drug monitoring, there is no personalized cancer care. Clin Pharmacol Ther 2013;93(3):228-30
   PubMed Web of Science ®Google Scholar
• Minne L, Eslami S, Kuiper RA, et al. Five years of therapeutic drug monitoring in the intensive care did not change vancomycin prescription behaviour: perceived needs for decision support. Minerva Anestesiol 2012;78(6):684-92
   PubMed Web of Science ®Google Scholar
• Spina SP, Ensom MHH. Clinical pharmacokinetic monitoring of midazolam in critically ill patients. Pharmacotheraphy 2007;27(3):389-98
   PubMed Web of Science ®Google Scholar
• Revilla N, Martín-Suárez A, Pérez MP, et al. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. Br J Clin Pharmacol 2010;70(2):201-12
   PubMed Web of Science ®Google Scholar
• Fernández de Gatta M M, Revilla N, Calvo MV, et al. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med 2007;33(2):279-85
   PubMed Web of Science ®Google Scholar
• Fernández de Gatta MM, Calvo MV, Ardanuy R, et al. Evaluation of population pharmacokinetic models for amikacin dosage. J Pharm Pharmacol 2009;61(6):759-66
   PubMed Web of Science ®Google Scholar
• Sinnollareddy M, Peake SL, Roberts MS, et al. Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review. Int J Antimicrob Ag 2012;39(1):1-10
   PubMed Web of Science ®Google Scholar
• Hayashi Y, Lipman J, Udy AA, et al. beta-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia. Int J Antimicrob Agents 2013;41(2):162-6
   PubMed Web of Science ®Google Scholar
• Tröger U, Drust A, Martens-Lobenhoffer J, et al. Decreased meropenem levels in Intensive Care Unit patients with augmented renal clearance: benefit of therapeutic drug monitoring. Int J Antimicrob Agents 2012;40(4):370-2
   PubMed Web of Science ®Google Scholar
• Dong Y, Chbat NW, Gupta A, et al. Systems modelling and simulation applications for critical care medicine. Ann Intensive Care 2012;2(1):18
   Google Scholar
• Khachman D, Conil JM, Georges B, et al. Optimizing ciprofloxacin dosing in intensive care unit patients through the use of population pharmacokinetic-pharmacodynamic analysis and Monte Carlo simulations. J Antimicrob Chemother 2011;66(8):1798-809
   PubMed Web of Science ®Google Scholar
• Georges B, Conil JM, Ruiz S, et al. Ceftazidime dosage regimen in intensive care unit patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations. Br J Clin Pharmacol 2012;73(4):588-96
   PubMed Web of Science ®Google Scholar
• Roos JF, Lipman J, Kirkpatrick CM. Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria. Intensive Care Med 2007;33(5):781-8
   PubMed Web of Science ®Google Scholar
• Barr J, Egan TD, Sandoval NF, et al. Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model. Anesthesiology 2001;95(2):324-33
   PubMed Web of Science ®Google Scholar
• Frenkel C, Schuttler J, Ihmsen H, et al. Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. Intensive Care Med 1995;21(12):981-8
   PubMed Web of Science ®Google Scholar
• Romano S, Fdez de Gatta MM, Calvo V, et al. Influence of clinical diagnosis in the population pharmacokinetics of amikacin in intensive care unit patients. Clin Drug Investig 1998;15(5):435-44
   PubMed Web of Science ®Google Scholar
• Bastiaans DE, Swart EL, van Akkeren JP, Derijks LJ. Pharmacokinetics of midazolam in resuscitated patients treated with moderate hypothermia. Int J Clin Pharm 2013;35(2):210-16
   Google Scholar
• Lukas JC, Karikas G, Gazouli M, et al. Pharmacokinetics of teicoplanin in an ICU population of children and infants. Pharm Res 2004;21(11):2064-71
   PubMed Web of Science ®Google Scholar
• Conil JM, Georges B, Ruiz S, et al. Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations. Br J Clin Pharmacol 2011;71(1):61-71
   PubMed Web of Science ®Google Scholar
• Heming N, Faisy C, Urien S. Population pharmacodynamic model of bicarbonate response to acetazolamide in mechanically ventilated chronic obstructive pulmonary disease patients. Crit Care 2011;15(5):R213
   PubMedGoogle Scholar
• Georgs B, Conil JM, Seguin T, et al. Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation and reason for admission. Antimicrob Agents Chemother 2009;53:4483-9
   PubMed Web of Science ®Google Scholar
• Arnold HM, Hollands JM, Skrupky LP, Micek ST. Optimizing sustained use of sedation in mechanically ventilated patients: focus on safety. Curr Drug Saf 2010;5:6-12
   PubMedGoogle Scholar
• Iirola T, Ihmsen H, Laitio R, et al. Population pharmacokinetics of dexmedetomidine during long-term sedation in intensive care patients. Br J Anaesth 2012;108(3):460-8
   PubMed Web of Science ®Google Scholar
• Roberts JA, Taccone FS, Udy AA, et al. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 2011;55:2704-9
   PubMed Web of Science ®Google Scholar
• Kees MG, Schaeftlein A, Haeberle HA, et al. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients. J Antimicrob Chemother 2013;68(6):1331-7
   PubMed Web of Science ®Google Scholar
• Swart EL, Zuideveld KP, Jongh J, et al. Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. Br J Clin Pharmacol 2003;57(2):135-45
   Web of Science ®Google Scholar
• Swart EL, Zuideveld KP, de Jongh J, et al. Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients. Br J Clin Pharmacol 2004;57(2):135-45
   PubMed Web of Science ®Google Scholar
• Lugo-Goytia G, Castañeda-Hernández G. Bayesian approach to control of amikacin serum concentrations in critically ill patients with sepsis. Ann Pharmacother 2000;34(12):1389-94
   PubMed Web of Science ®Google Scholar
• Tod M, Padoin C, Minozzi C, et al. Population pharmacokinetic study of isepamicin with intensive care unit patients. Antimicrob Agents Chemother 1996;40(4):983-7
   PubMed Web of Science ®Google Scholar
• Roberts JA, Roberts MS, Semark A, et al. Antibiotic dosing in the ‘at risk' critically ill patient: linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. BMC Anesthesiol 2011;11:3
   PubMed Web of Science ®Google Scholar
• Wang Y. Derivation of various NONMEM estimation methods. J Pharmacokinet Pharmacodyn 2007;34:575-93
   PubMed Web of Science ®Google Scholar
• Vermes A, Math t RA, van der Sijs IH, et al. Population pharmacokinetics of flucytosine: comparison and validation of three models using STS, NPEM, and NONMEM. Ther Drug Monit 2000;22(6):676-87
   PubMed Web of Science ®Google Scholar
• Jelliffe RW. Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy. Ther Drug Monit 2012;34(4):368-77
   PubMed Web of Science ®Google Scholar
• Matar KM, Al-lanqawi Y, Abdul-Malek K, Jelliffe R. Amikacin population pharmacokinetics in critically ill Kuwaiti patients. Biomed Res Int 2013;2013:202818
   Google Scholar
• Steyerberg EW, Bleeker SE, Moll HA, et al. Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J Clin Epidemiol 2003;56(5):441-7
   PubMed Web of Science ®Google Scholar
• Pea F, Bertolissi M, Di Silvestre A, et al. TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients. Int J Antimicrob Ag 2002;20(5):326-32
   PubMed Web of Science ®Google Scholar
• Reimann IR, Meier-Hellmann A, Traut T, et al. Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients. Exp Toxicol Pathol 2003;54(5-6):493-8
   PubMed Web of Science ®Google Scholar
• Polard E, Le Bouquin V, Le Corre P, et al. Non steady state and steady state PKS Bayesian forecasting and vancomycin pharmacokinetics in ICU adult patients. Ther Drug Monit 1999;21(4):395-403
   PubMed Web of Science ®Google Scholar
• Macdonald I, Staatz CE, Jelliffe RW, Thomson AH. Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery. Ther Drug Monit 2008;30(1):67-74
   PubMed Web of Science ®Google Scholar
• Mouton JW, Punt N, Vinks AA. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin Ther 2005;27(6):762-72
   PubMed Web of Science ®Google Scholar
• Zazo H, Martín-Suárez A, Lanao JM. Evaluating amikacin dosage regimens in ICU patients: a PK/PD analysis using Monte Carlo simulation. Int J Antimicrob Agents 2013. Available from: http://dx.doi.org/10.1016/j.ijantimicag.2013.04.021
   PubMed Web of Science ®Google Scholar
• Crews KR, Hicks JK, Pui CH, et al. Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther 2012;92(4):467-75
   PubMed Web of Science ®Google Scholar
• Freeman BD, Mcleod HL. Challenges of implementing pharmacogenetics in the critical care environment. Nat Rev Drug Discov 2004;3:88-93
   PubMed Web of Science ®Google Scholar
• Empey PE. Genetic predisposition to adverse drug reactions in the intensive care unit. Crit Care Med 2010;38:S106-16
   PubMed Web of Science ®Google Scholar
• Campbell SC, Spigarelli MG, Courter J, Sherwin CMT. Metabolic and toxicological considerations for sepsis drug treatments. Expert Opin Drug Metab Toxicol 2013;9:79-89
   PubMed Web of Science ®Google Scholar
• Johnson TN, Boussery K, Rowland-Yeo K, et al. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet 2010;49:189-206
   PubMed Web of Science ®Google Scholar
• Rissmann R, Dubois EA, Franson KL, Cohen AF. Concept-based learning of personalized prescribing. Br J Clin Pharmacol 2012;74:589-96
   PubMed Web of Science ®Google Scholar
• Sim SC, Altman RB, Ingelman–Sundberg M. Databases in the area of pharmacogenetics. Hum Mutat 2011;32:526-31
   PubMed Web of Science ®Google Scholar
• Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012;92(4):414-17
   PubMed Web of Science ®Google Scholar